Related Experiment Video

Updated: Jun 24, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a

A Bitto1, B P Burnett, F Polito

  • 1Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy.

British Journal of Pharmacology
|March 24, 2009
PubMed
Abstract

Insights

Genistein aglycone shows promise in treating glucocorticoid-induced osteoporosis (GIO), outperforming alendronate in key bone health markers. This research suggests genistein as a potential alternative therapy for secondary osteoporosis.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Glucocorticoid-induced osteoporosis (GIO) is a primary cause of secondary osteoporosis.
  • Genistein aglycone's potential in treating post-menopausal osteopenia is suggested but requires comparative efficacy data.
  • Current treatments for GIO lack comprehensive comparative studies.

Purpose of the Study:

  • To investigate the bone-protective effects of genistein aglycone compared to alendronate in an experimental model of GIO.
  • To evaluate genistein's efficacy in improving bone mineral density, content, and strength.
  • To assess the impact of genistein on bone formation and resorption markers.

Main Methods:

  • Glucocorticoid-induced osteoporosis (GIO) was established in 28 female Sprague-Dawley rats using methylprednisolone (MP).
  • MP-treated rats were randomized to receive vehicle, genistein aglycone, or alendronate for 60 days.
  • Bone mineral density, content, breaking strength, and biochemical markers (bone-alkaline phosphatase, carboxy-terminal collagen cross links) were assessed.

Main Results:

  • Genistein aglycone significantly increased bone mineral density, bone mineral content, and femur breaking strength compared to alendronate.
  • Genistein aglycone demonstrated a greater increase in bone-alkaline phosphatase (bone formation) and reduction in carboxy-terminal collagen cross links (bone resorption) than alendronate.
  • Both genistein aglycone and alendronate treatments improved bone histology and histological scores.

Conclusions:

  • Genistein aglycone exhibits superior efficacy over alendronate in improving bone health parameters in experimental GIO.
  • The findings support genistein aglycone as a potential therapeutic alternative for managing secondary osteoporosis.
  • Further clinical studies are warranted to confirm genistein's efficacy in human patients.

More Related Videos

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.